Royal Prima Tbk PT

Royal Prima Tbk PT has a market price of 80.0 and a market cap of 270,265,616,400. The company's price-to-book ratio is 0.29, and its price-to-tangible-book ratio is also 0.29, indicating that the company is trading at a significant discount to its book value. The enterprise value to EBITDA ratio is negative at -11.59, reflecting the company's current operating losses. The enterprise value to revenue ratio is 0.78, suggesting that the company is valued at a discount relative to its revenue. The company's profitability metrics are concerning, with a return on equity of -2.32% and a return on assets of -2.08%, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of 21,817,384,810 and an operating loss of 22,896,226,940, indicating a challenging operating environment. The gross profit of 72,799,843,840 is insufficient to cover operating expenses, contributing to the net loss. Royal Prima Tbk PT's revenue is concentrated across three segments: RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The company operates in Indonesia, with no disclosed geographic diversification. The lack of geographic diversification may expose the company to regional economic and regulatory risks. The company's revenue concentration in a single country could be a risk factor, especially in the healthcare sector, which is subject to regulatory changes and public health events. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's operating cash flow is 4,138,350,040, and its free cash flow is 30,723,255,410, indicating that the company generates positive cash flow from operations despite its net loss. The capital expenditure of -10,951,440,300 suggests that the company is investing in its operations, which could support future growth. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged, which reduces financial risk. The current ratio of 2.01 suggests that the company has sufficient current assets to cover its current liabilities. The company's liquidity position is further supported by its cash and equivalents of 5,000,000,000. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's financial statements show a consistent pattern of operating losses, which may be a concern for investors. The company's ability to generate positive free cash flow despite these losses is a positive sign, but the long-term sustainability of this performance is uncertain.